Drug Development
The development of nicotinic acetylcholine receptor agonists began in the early 1990s after the discovery of nicotine’s positive effects on animal memory. The development of nicotinic acetylcholine receptor agonists has come a long way since then. The nicotinic acetylcholine receptor agonist are gaining increasing attention as drug candidates for multiple central nervous system disorders such as Alzheimer's disease, schizophrenia, attention-deficit hyperactivity disorder (ADHD) and nicotine addiction. Nicotinic acetylcholine receptors are receptors found in the central nervous system, the peripheral nervous systems and skeletal muscles. They are ligand-gated ion channels with binding sites for acetylcholine as well as other agonists. When agonists bind to a receptor it stabilizes the open state of the ion channel allowing influx of cations.
In 2009 there were at least five drugs on the market that affect the nicotinic acetylcholine receptors.
| Quinuclidine Carbamates | Quinuclidine Amides | Quinuclidine Ethers |
Read more about this topic: Nicotinic Agonist
Famous quotes containing the words drug and/or development:
“He’d been numb a long time, years. All his nights down Ninsei, his nights with Linda, numb in bed and numb at the cold sweating center of every drug deal. But now he’d found this warm thing, this chip of murder. Meat, some part of him said. It’s the meat talking, ignore it.”
—William Gibson (b. 1948)
“America is a country that seems forever to be toddler or teenager, at those two stages of human development characterized by conflict between autonomy and security.”
—Anna Quindlen (b. 1952)